Table 1.
Patient characteristics for all the patients treated with DSCs
| Characteristics | Group 1, n = 17 | Group 2, n = 21 | p value |
|---|---|---|---|
| Sex (M/F) | 9/8 | 16/5 | .18 |
| Age at GVHD, years, median (range) | 54.5 (0.9–65.6) | 48.9 (1.6–72.4) | .33 |
| Children (<19 years of age) | 2 | 3 | .33 |
| Diagnosis (malignant/nonmalignant) | 14/3 | 17/4 | 1.00 |
| Disease status (high risk/low risk) | 9/8 | 14/7 | .51 |
| Conditioning (MAC/RIC) | 8/9 | 4/17 | .09 |
| ATG (yes/no) | 10/7 | 14/7 | .74 |
| GVHD prophylaxis | .63 | ||
| CsA/MTX | 13 | 13 | |
| TAC/SIR | 3 | 6 | |
| CsA/MTX/Cy | 1 | 2 | |
| Donor SIB/MUD/CB/haplo | 6/10/1/0 | 6/14/0/1 | .52 |
| Graft source (PBSCs/BM/CB) | 14/2/1 | 16/5/0 | .36 |
| GVHD grade at time of intervention (2/3) | 2/15 | 6/15 | .26 |
| GVHD localization (gut and other/only liver) | 17/0 | 21/0 | 1.00 |
| Fungal prophylaxis (yes/no) | 17/0 | 21/0 | 1.00 |
| CMV (double‐neg./any pos.) | 3/14 | 7/14 | .46 |
| GVHD after DLI (yes/no) | 0/17 | 2/19 | .49 |
| HSCT/DLI steroids, days (range) | 59 (10–375) | 64 (5–265) | .97 |
| Days with steroids median (range) | 13 (1–37) | 7 (0–35) | .09 |
| Number of infusions (range) | 1 (1–5) | 2 (1–6) | .002 |
| Cell dose (range) | 2.0 (0.9–2.8) | 1.2 (0.9–2.9) | <.001 |
| Cell passage (range) | 2 (2–4) | 4 (2–4) | <.001 |
| Viability, % (range) | 90 (70–97) | 95 (69–100) | <.001 |
Abbreviations: ATG, antithymocyte globulin; BM, bone marrow; CB, cord blood; CMV, cytomegalovirus; CsA, cyclosporine A; Cy, cyclophosphamide; DLI, donor lymphocyte infusion; DSCs, decidua stromal cells; F, female; GVHD, graft‐versus‐host disease; HSCT, allogeneic hematopoietic stem cell transplantation; M, male; MAC, myeloablative conditioning; MTX, methotrexate; MUD, matched unrelated donor; neg., negative; PBSCs, peripheral blood stem cells; pos., positive; RIC, reduced‐intensity conditioning; SIB, sibling donor; SIR, sirolimus; TAC, tacrolimus.